On Monday, the fascinating conclusion to a lengthy court battle between Swiss drugmaker Novartis (NYSE: NVS ) and the Supreme Court of India was revealed. The court ruled that Novartis' top-selling blockbuster drug Glivec (which is branded as Gleevec in the U.S.) should not be granted patent protection, which means that generic competitors can continue manufacturing their own versions of the drug in India. As the debate continues over the long-term implications of this controversial decision, investors are wondering how this ruling actually impacts Novartis' sales. In the following video, health care analyst Max Macaluso discusses the effect of this decision on Novartis' top line.
What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: What's Really Eating At America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.